85%Confidence
0Views
FDASource
2026-03-28Date
Summary
Cipla's Nilotinib Capsules recall due to stability test failures indicates potential quality control issues at its India manufacturing site, which could impact its US market reputation and supply chain reliability. This may create opportunities for competitors in the oncology generic drug market, particularly for leukemia treatments.
Actionable: Monitor Cipla's manufacturing compliance reports and consider diversifying supplier sources for nilotinib or similar oncology generics.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now